Adial Pharmaceuticals (ADIL) Competitors $0.36 +0.00 (+1.03%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$0.36 0.00 (-0.44%) As of 10/24/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. KZR, XCUR, RNTX, SONN, IMA, CVKD, LNAI, ENLV, DARE, and PASGShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Kezar Life Sciences (KZR), Exicure (XCUR), Rein Therapeutics (RNTX), Sonnet BioTherapeutics (SONN), ImageneBio (IMA), Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), Enlivex Therapeutics (ENLV), Dare Bioscience (DARE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Kezar Life Sciences Exicure Rein Therapeutics Sonnet BioTherapeutics ImageneBio Cadrenal Therapeutics Lunai Bioworks Enlivex Therapeutics Dare Bioscience Passage Bio Adial Pharmaceuticals (NASDAQ:ADIL) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has better earnings and valuation, ADIL or KZR? Kezar Life Sciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$13.20M-$1.05-0.35Kezar Life SciencesN/AN/A-$83.74M-$9.69-0.64 Do analysts rate ADIL or KZR? Adial Pharmaceuticals currently has a consensus price target of $4.75, suggesting a potential upside of 1,209.98%. Kezar Life Sciences has a consensus price target of $6.00, suggesting a potential downside of 2.60%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Adial Pharmaceuticals is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Kezar Life Sciences 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Do insiders & institutionals have more ownership in ADIL or KZR? 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 4.3% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor ADIL or KZR? In the previous week, Kezar Life Sciences had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for Kezar Life Sciences and 3 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.63 beat Kezar Life Sciences' score of 0.10 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kezar Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ADIL or KZR? Adial Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Is ADIL or KZR more profitable? Kezar Life Sciences' return on equity of -63.51% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -191.31% -153.59% Kezar Life Sciences N/A -63.51%-52.13% SummaryAdial Pharmaceuticals beats Kezar Life Sciences on 9 of the 14 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.83M$219.07M$6.23B$10.66BDividend YieldN/A3.81%5.71%4.82%P/E Ratio-0.353.2830.4330.35Price / SalesN/A5,399.00594.57134.18Price / CashN/A13.1937.0161.44Price / Book0.5790.1312.046.60Net Income-$13.20M-$90.99M$3.32B$276.82M7 Day Performance0.75%0.21%1.88%2.53%1 Month Performance8.34%5.28%7.68%3.71%1 Year Performance-67.04%495.29%56.01%33.82% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.1823 of 5 stars$0.36+1.0%$4.75+1,210.0%-67.0%$7.83MN/A-0.3520Analyst ForecastKZRKezar Life Sciences3.0013 of 5 stars$4.30+0.2%$9.00+109.3%-23.2%$31.81M$7M-0.4560XCURExicure1.7647 of 5 stars$5.02-1.6%N/A+114.6%$31.73M$500K-1.2950Gap UpRNTXRein Therapeutics3.2156 of 5 stars$1.32-1.5%$10.00+657.6%N/A$30.77MN/A-0.499SONNSonnet BioTherapeutics2.2775 of 5 stars$4.42+2.6%$20.00+352.4%-21.6%$30.29M$20K0.0010News CoverageIMAImageneBio3.661 of 5 stars$7.56-1.0%$35.50+369.6%-61.0%$30.28M$3.50M-0.9870News CoverageAnalyst ForecastGap UpCVKDCadrenal Therapeutics3.2716 of 5 stars$14.14+1.1%$32.00+126.3%-15.7%$28.94MN/A-1.594Analyst ForecastLNAILunai BioworksN/A$1.24+1.6%N/AN/A$28.74MN/A-0.1620ENLVEnlivex Therapeutics2.9788 of 5 stars$1.15+3.2%$10.00+773.4%-29.9%$27.93MN/A-1.9870DAREDare Bioscience2.3515 of 5 stars$2.07+0.2%$10.00+384.3%-39.7%$27.84M$10K-0.9630Analyst ForecastPASGPassage Bio3.5743 of 5 stars$8.75+0.7%$75.67+764.8%-44.7%$27.83MN/A-0.48130 Related Companies and Tools Related Companies Kezar Life Sciences Alternatives Exicure Alternatives Rein Therapeutics Alternatives Sonnet BioTherapeutics Alternatives ImageneBio Alternatives Cadrenal Therapeutics Alternatives Lunai Bioworks Alternatives Enlivex Therapeutics Alternatives Dare Bioscience Alternatives Passage Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADIL Stock Alerts